• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
  • 2
    Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005; 235: 728-739.
  • 3
    Ikai I, Arii S, Okazaki M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2007; 37: 676-691.
  • 4
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
  • 5
    Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol. 1990; 5: 616-626.
  • 6
    Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993; 18: 1121-1126.
  • 7
    Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995; 1: 73-81.
  • 8
    Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999; 210: 655-661.
  • 9
    Morimoto M, Sugimori K, Shirato K, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology. 2002; 35: 1467-1475.
  • 10
    Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000; 214: 761-768.
  • 11
    Livraghi T, Goldberg SN, Monti F, et al. Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases. Radiology. 1997; 202: 205-210.
  • 12
    Kurokohchi K, Watanabe S, Masaki T, et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int J Oncol. 2002; 21: 611-615.
  • 13
    de Baere T, Bessoud B, Dromain C, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol. 2002; 178: 53-59.
  • 14
    Kobayashi M, Ikeda K, Kawamura Y, et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma–direct ablative effects and a long-term outcome. Liver Int. 2007; 27: 353-359.
  • 15
    Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002; 13: 1225- 1232.
  • 16
    Sugimori K, Morimoto M, Shirato K, et al. Radiofrequency ablation in a pig liver model: effect of transcatheter arterial embolization on coagulation diameter and histologic characteristics. Hepatol Res. 2002; 24: 164-173.
  • 17
    Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002; 68: 827-831.
  • 18
    Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer. 1998; 83: 2302-2311.
  • 19
    Shirato K, Morimoto M, Tomita N, et al. Hepatocellular carcinoma: percutaneous radiofrequency ablation using expandable needle electrodes and the double-insertion technique. Hepatogastroenterology. 2002; 49: 1481-1483.
  • 20
    Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14( 9 pt 2): S199-S202.
  • 21
    Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232: 381-391.
  • 22
    Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999; 353: 1676-1677.
  • 23
    Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994; 74: 817-825.
  • 24
    Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000; 217: 119-126.
  • 25
    Nakamura H, Hashimoto T, Oi H, et al. Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins. Acta Radiol. 1990; 31: 347-349.
  • 26
    Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001; 220: 420-427.
  • 27
    Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002; 222: 797-804.
  • 28
    Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol. 2002; 179: 93-101.
  • 29
    Holdener EE, Hansen HH, Host H, et al. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs. 1985; 3: 63-66.
  • 30
    Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999; 20: 47-53.
  • 31
    Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006; 16: 661-669.
  • 32
    Yu SC, Leung TW, Lau WY, et al. A comparison of 3 transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans. Cardiovasc Intervent Radiol. 2008; 31: 289-298.
  • 33
    Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25: 87-92.
  • 34
    Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001; 91: 561-569.
  • 35
    Okusaka T, Okada S, Ueno H, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000; 58: 293-299.
  • 36
    Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using 3 tumor markers. Hepatology. 2006; 44: 1518-1527.
  • 37
    Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than 3 centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986; 90: 289-298.
  • 38
    Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993; 18: 47-53.
  • 39
    Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990; 12: 1420-1432.
  • 40
    Aoyagi Y, Isemura M, Yosizawa Z, et al. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta. 1985; 830: 217-223.
  • 41
    Yamashita F, Tanaka M, Satomura S, Tanikawa K. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol. 1995; 7: 627-633.
  • 42
    Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology. 2008; 55: 1454-1457.
  • 43
    Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007; 72( suppl 1): 98-103.
  • 44
    Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007; 13: 1003-1009.